Valion Bio, Inc.
VBIO
$1.10
-$0.01-0.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 302.00K | 482.00K | 462.00K | 516.00K | 780.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 302.00K | 482.00K | 462.00K | 516.00K | 780.00K |
| Cost of Revenue | 343.00K | 343.00K | 134.00K | 212.00K | 359.00K |
| Gross Profit | -41.00K | -41.00K | 148.00K | 124.00K | 241.00K |
| SG&A Expenses | 4.77M | 3.76M | 3.33M | 2.99M | 3.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.90M | 5.92M | 4.85M | 4.24M | 4.48M |
| Operating Income | -7.90M | -6.22M | -5.17M | -4.50M | -4.48M |
| Income Before Tax | -7.99M | -6.32M | -5.16M | -4.49M | -4.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.99 | -6.32 | -5.16 | -4.49 | -4.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.88M | -7.51M | -6.34M | -5.68M | -5.66M |
| EBIT | -7.90M | -6.22M | -5.17M | -4.50M | -4.48M |
| EBITDA | -7.89M | -6.22M | -5.17M | -4.50M | -4.47M |
| EPS Basic | -7.85 | -8.17 | -10.10 | -13.27 | -27.91 |
| Normalized Basic EPS | -4.46 | -2.45 | -3.73 | -5.72 | -14.86 |
| EPS Diluted | -7.85 | -8.17 | -10.10 | -13.27 | -27.91 |
| Normalized Diluted EPS | -4.46 | -2.45 | -3.73 | -5.72 | -14.86 |
| Average Basic Shares Outstanding | 3.95M | 3.09M | 2.13M | 1.48M | 973.80K |
| Average Diluted Shares Outstanding | 3.95M | 3.09M | 2.13M | 1.48M | 973.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |